The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions-Reference-Cited by-同舟云学术

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

Published:2014-03-03 Issue:4 Volume:68 Page:465-470
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Adler G.¹,Mueller B.²,Articus K.²

Affiliation:

1. Institut für Studien zur Psychischen Gesundheit (ISPG) Mannheim Germany

2. Novartis Pharma GmbH Nuremberg Germany

Funder

Novartis Pharma GmbH

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.12374

Reference13 articles.

1. Drug delivery strategies for Alzheimer's disease treatment

2. Impact of Rivastigmine Patch and Capsules on Activities of Daily Living in Alzheimer’s Disease

3. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

4. Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimers Disease

5. Rivastigmine Transdermal Patch

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translation from Preclinical Research to Clinical Trials: Transdermal Drug Delivery for Neurodegenerative and Mental Disorders;Pharmaceutical Research;2024-06

2. Phytochemical Compounds Loaded to Nanocarriers as Potential Therapeutic Substances for Alzheimer’s Disease-Could They be Effective?;Current Pharmaceutical Design;2022-08

3. Impact of interventions by a community pharmacist on care burden for people with dementia: development and randomized feasibility trial of an intervention protocol;Pilot and Feasibility Studies;2022-06-02

4. A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment;Archives of Osteoporosis;2022-04-04

5. Memantine-Derived Schiff Bases as Transdermal Prodrug Candidates;ACS Omega;2022-03-28